Artelis Bio

Artelis is a Belgian biotechnology company specializing in the development of high-density cell culture processes and innovative bioreactor technologies. The company is best known for inventing the iCELLis bioreactor, a high-density, single-use fixed-bed bioreactor designed to simplify the scale-up of viral vector production for gene therapies and vaccines. Artelis provides bioprocess intensification solutions that significantly reduce the footprint and cost of manufacturing complex biologics. Their technology addresses the critical challenges of transitioning from laboratory-scale processes to industrial-scale production. Following its acquisition by Pall Corporation in 2010, Artelis's technologies have become industry standards for adherent cell culture in the life sciences sector. The company's expertise continues to play a vital role in the advancement of the global cell and gene therapy manufacturing landscape.